BG104034A - Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect - Google Patents

Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect

Info

Publication number
BG104034A
BG104034A BG104034A BG10403499A BG104034A BG 104034 A BG104034 A BG 104034A BG 104034 A BG104034 A BG 104034A BG 10403499 A BG10403499 A BG 10403499A BG 104034 A BG104034 A BG 104034A
Authority
BG
Bulgaria
Prior art keywords
effect
preparation
pharmaceutical compounds
antidepressive
parkinson syndrome
Prior art date
Application number
BG104034A
Other languages
Bulgarian (bg)
English (en)
Inventor
Marvin Yu
Victor JACEWICZ
Evgeny Shapiro
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9711095.1A external-priority patent/GB9711095D0/en
Priority claimed from GBGB9714875.3A external-priority patent/GB9714875D0/en
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of BG104034A publication Critical patent/BG104034A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG104034A 1997-05-29 1999-12-17 Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect BG104034A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9711095.1A GB9711095D0 (en) 1997-05-29 1997-05-29 Novel process
GBGB9714875.3A GB9714875D0 (en) 1997-07-15 1997-07-15 Novel process
PCT/US1998/011057 WO1998053824A1 (en) 1997-05-29 1998-05-29 Novel process

Publications (1)

Publication Number Publication Date
BG104034A true BG104034A (en) 2000-11-30

Family

ID=26311618

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104034A BG104034A (en) 1997-05-29 1999-12-17 Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect

Country Status (22)

Country Link
US (3) US6489347B1 (xx)
EP (1) EP0986389B1 (xx)
JP (1) JP2002514222A (xx)
CN (1) CN1268889A (xx)
AP (1) AP9901698A0 (xx)
AT (1) ATE279393T1 (xx)
AU (1) AU7708998A (xx)
BG (1) BG104034A (xx)
BR (1) BR9809687A (xx)
CA (1) CA2291251A1 (xx)
DE (1) DE69827000D1 (xx)
EA (1) EA199901098A1 (xx)
HU (1) HUP0003958A3 (xx)
ID (1) ID24383A (xx)
IL (1) IL133140A0 (xx)
NO (1) NO995796D0 (xx)
NZ (1) NZ501285A (xx)
OA (1) OA11223A (xx)
PL (1) PL337513A1 (xx)
SK (1) SK159899A3 (xx)
TR (1) TR199902929T2 (xx)
WO (1) WO1998053824A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6438585B2 (en) * 1998-05-29 2002-08-20 Research In Motion Limited System and method for redirecting message attachments between a host system and a mobile data communication device
WO2000026187A1 (en) * 1998-11-02 2000-05-11 Synthon B.V. Process for producing 4-arylpiperidine-3-carbinols and related compounds
US20010053862A1 (en) * 1998-12-22 2001-12-20 Bruce Ronsen Process for preparing arylpiperidine carbinol intermediates and derivatives
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
IT1313702B1 (it) * 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6833458B2 (en) * 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
JP2004520333A (ja) 2001-01-04 2004-07-08 フエルレル インターナショナル，ソシエダッド アノニマ （±）−トランス−４−ｐ−フルオロフェニル−３−ヒドロキシメチル−１−メチルピペリジンの製造方法。
CA2464327A1 (en) 2001-10-22 2003-05-30 Synthon B.V. N-formyl derivatives of paroxetine
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
CN112645951A (zh) * 2020-12-23 2021-04-13 上海博栋化学科技有限公司 由长春布宁合成的磺酸锍盐类光产酸剂及其合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798432A (en) * 1945-02-27 1957-07-09 Leo T Meister Delay action fuse
US2498432A (en) 1946-07-08 1950-02-21 Hoffmann La Roche 1-branched lower alkyl-4-phenyl-4-acyloxy-piperidines and their acid addition salts
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
US4593036A (en) 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
EP0223334B1 (en) 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
GB8520154D0 (en) 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
GB8714707D0 (en) 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
IL98757A (en) 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
US5258517A (en) 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
ES2102295B1 (es) 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
US5856493A (en) 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
HUP9900318A3 (en) 1995-05-17 2001-09-28 Novo Nordisk As Process for preparing 4-aryl-piperidine derivatives
ATE242213T1 (de) 1995-09-07 2003-06-15 Hoffmann La Roche Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
EP0812827B1 (en) 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation
CA2284732C (en) 1997-04-07 2008-06-17 Georgetown University Analogs of cocaine
WO2000026187A1 (en) 1998-11-02 2000-05-11 Synthon B.V. Process for producing 4-arylpiperidine-3-carbinols and related compounds
US6051812A (en) * 1998-11-16 2000-04-18 Walker; Lawrence Snow and ice melting blanket device

Also Published As

Publication number Publication date
EP0986389A4 (en) 2001-09-12
US20020133011A1 (en) 2002-09-19
DE69827000D1 (de) 2004-11-18
US6716985B2 (en) 2004-04-06
PL337513A1 (en) 2000-08-28
CA2291251A1 (en) 1998-12-03
NO995796L (no) 1999-11-26
EP0986389A1 (en) 2000-03-22
HUP0003958A3 (en) 2001-06-28
EA199901098A1 (ru) 2000-08-28
TR199902929T2 (xx) 2000-06-21
OA11223A (en) 2003-06-17
JP2002514222A (ja) 2002-05-14
IL133140A0 (en) 2001-03-19
EP0986389B1 (en) 2004-10-13
HUP0003958A2 (hu) 2001-05-28
BR9809687A (pt) 2000-07-11
WO1998053824A1 (en) 1998-12-03
US6489347B1 (en) 2002-12-03
NO995796D0 (no) 1999-11-26
ATE279393T1 (de) 2004-10-15
NZ501285A (en) 2001-10-26
ID24383A (id) 2000-07-13
AU7708998A (en) 1998-12-30
US20040147754A1 (en) 2004-07-29
AP9901698A0 (en) 1999-12-31
CN1268889A (zh) 2000-10-04
SK159899A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
MXPA02000973A (es) Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
MXPA02011458A (es) Derivados de acilfenilurea, metodos para su produccion y uso de los mismos como farmacos.
AP2002002637A0 (en) Novel piperazine
HK1023987A1 (en) Sulphinic acid derivatives, method for producing, and their use
MX9700886A (es) Nuevas oxazolidinonas sustituidas.
BG105527A (en) Nonsteroid antiinflammatories
TR200102800T2 (tr) Yeni bileşikler.
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
PL289487A1 (en) Method of producing new aminophenol derivatives
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
MX9700273A (es) Benzamidinas sustituidas, su preparacion y empleo como sustancias medicamentosas.
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
BG104034A (en) Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
AU6993600A (en) Inorganic coating composition, a method for producing same and the use thereof
JO2249B1 (en) A compound of 6.3-dialkyl-6.5-dihydro-4-hydroxy-biran-2-one
NZ325235A (en) New phenylamidine derivatives, a process for preparing the same and their use as medicaments
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
BG105766A (en) New process for preparing pesticidal intermediates
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
IN187760B (xx)
NZ510116A (en) Tricyclic delta-3-piperidines as pharmaceuticals
BG105326A (en) Novel benzoylguanadine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
HK1051845A1 (en) Substituted 1 and 2 naphthol mannich bases
IL148161A0 (en) Process for the preparation of 2-cyanopyridines